SG11201912882QA - Treatment of inflammatory diseases with inhibitors of c5a activity - Google Patents
Treatment of inflammatory diseases with inhibitors of c5a activityInfo
- Publication number
- SG11201912882QA SG11201912882QA SG11201912882QA SG11201912882QA SG11201912882QA SG 11201912882Q A SG11201912882Q A SG 11201912882QA SG 11201912882Q A SG11201912882Q A SG 11201912882QA SG 11201912882Q A SG11201912882Q A SG 11201912882QA SG 11201912882Q A SG11201912882Q A SG 11201912882QA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- activity
- treatment
- inflammatory diseases
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17177657 | 2017-06-23 | ||
| EP17189938 | 2017-09-07 | ||
| PCT/EP2018/065676 WO2018234118A1 (en) | 2017-06-23 | 2018-06-13 | TREATMENT OF INFLAMMATORY DISEASES BY INHIBITORS OF C5A ACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912882QA true SG11201912882QA (en) | 2020-01-30 |
Family
ID=62636193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912882QA SG11201912882QA (en) | 2017-06-23 | 2018-06-13 | Treatment of inflammatory diseases with inhibitors of c5a activity |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3642230A1 (ja) |
| JP (1) | JP2020524696A (ja) |
| KR (1) | KR20200020727A (ja) |
| CN (1) | CN111201241A (ja) |
| AU (1) | AU2018286754A1 (ja) |
| CA (1) | CA3066689C (ja) |
| IL (1) | IL271074A (ja) |
| SG (1) | SG11201912882QA (ja) |
| TW (1) | TWI786132B (ja) |
| WO (1) | WO2018234118A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45235A (fr) | 2016-06-14 | 2019-04-17 | Regeneron Pharma | Anticorps anti-c5 et leurs utilisations |
| EP3724226A1 (en) | 2017-12-13 | 2020-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| CA3132771A1 (en) * | 2019-03-14 | 2020-09-17 | Morphosys Ag | Antibodies targeting c5ar |
| TW202140553A (zh) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| US20230257454A1 (en) * | 2020-06-24 | 2023-08-17 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing c5a and uses thereof |
| CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| AU6501390A (en) | 1989-09-21 | 1991-04-18 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| AUPR833401A0 (en) * | 2001-10-17 | 2001-11-08 | University Of Queensland, The | G protein-coupled receptor antagonists |
| LT3385384T (lt) | 2004-02-12 | 2020-09-25 | Archemix Llc | Aptamero terapija, naudinga su komplementu susijusių ligų gydymui |
| WO2005092366A1 (en) * | 2004-03-26 | 2005-10-06 | Promics Pty Limited | TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS |
| WO2008009062A1 (en) | 2006-07-21 | 2008-01-24 | Promics Pty Ltd | Treatment for intimal hyperplasia and related conditions |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| PL2381778T3 (pl) * | 2008-12-22 | 2017-01-31 | Chemocentryx, Inc. | Antagoniści c5ar |
| GB0905790D0 (en) * | 2009-04-03 | 2009-05-20 | Alligator Bioscience Ab | Novel polypeptides and use thereof |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| JP2013529647A (ja) * | 2010-06-24 | 2013-07-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| ES2649490T3 (es) * | 2013-03-14 | 2018-01-12 | Alnylam Pharmaceuticals, Inc. | Composiciones de ARNi contra el componente C5 del complemento y métodos para su uso |
| US20160060351A1 (en) * | 2013-05-08 | 2016-03-03 | Novo Nordisk A/S | Use of C5AR Antagonists |
| WO2015140304A1 (en) * | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
| EP3194596A1 (en) | 2014-09-16 | 2017-07-26 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| WO2016061066A1 (en) | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of replicating a large scale eculizumab production cell culture |
| FR3030515B1 (fr) * | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| EP3313437A1 (en) | 2015-06-26 | 2018-05-02 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| NZ747259A (en) | 2016-04-04 | 2022-11-25 | Chemocentryx Inc | Soluble c5ar antagonists |
| IL261809B2 (en) * | 2017-04-03 | 2024-04-01 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5A activity |
-
2018
- 2018-06-13 KR KR1020197038211A patent/KR20200020727A/ko not_active Application Discontinuation
- 2018-06-13 JP JP2019570986A patent/JP2020524696A/ja active Pending
- 2018-06-13 EP EP18732016.3A patent/EP3642230A1/en active Pending
- 2018-06-13 WO PCT/EP2018/065676 patent/WO2018234118A1/en unknown
- 2018-06-13 TW TW107120362A patent/TWI786132B/zh active
- 2018-06-13 CN CN201880041303.4A patent/CN111201241A/zh active Pending
- 2018-06-13 SG SG11201912882QA patent/SG11201912882QA/en unknown
- 2018-06-13 AU AU2018286754A patent/AU2018286754A1/en active Pending
- 2018-06-13 CA CA3066689A patent/CA3066689C/en active Active
-
2019
- 2019-12-01 IL IL271074A patent/IL271074A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL271074A (en) | 2020-01-30 |
| TW201904611A (zh) | 2019-02-01 |
| AU2018286754A1 (en) | 2019-12-19 |
| EP3642230A1 (en) | 2020-04-29 |
| JP2020524696A (ja) | 2020-08-20 |
| KR20200020727A (ko) | 2020-02-26 |
| CN111201241A (zh) | 2020-05-26 |
| TWI786132B (zh) | 2022-12-11 |
| CA3066689C (en) | 2024-01-16 |
| CA3066689A1 (en) | 2018-12-27 |
| WO2018234118A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906485B (en) | Treatment of inflammatory diseases with inhibitors of c5a activity | |
| IL273693A (en) | Treatment of inflammatory disorders | |
| IL271074A (en) | Treatment of inflammatory diseases with c5a activity inhibitors | |
| IL253796A0 (en) | Therapeutically active compounds and methods of use | |
| IL251246A0 (en) | Therapeutically active compounds and methods of use | |
| IL249223A0 (en) | Mth1 inhibitors for the treatment of inflammatory and autoimmune conditions | |
| IL290980A (en) | Rna for the treatment of autoimmune diseases | |
| IL253118A0 (en) | Methods for treating inflammatory diseases | |
| IL264048A (en) | pde9 inhibitors for the treatment of peripheral diseases | |
| HK1252037A1 (zh) | 治療炎性疾病的方法 | |
| EP3503903A4 (en) | ASCAROSIDE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | |
| HK1258762A1 (zh) | Btk抑制劑gs-4059與選自jak、ask1、brd和/或mmp9抑制劑的抑制劑的組合，以治療癌症、過敏性病症、自身免疫疾病或發炎性疾病 | |
| RS61230B1 (sr) | Lečenje neuroloških bolesti | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| EP3197474C0 (en) | INHIBITORS OF NF-KAPPA-B ACTIVITY TO TREAT DISEASES AND CONDITIONS | |
| GB201515244D0 (en) | Treatment of inflammatory disease or condition | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| HK1243961A1 (zh) | 炎性病况的預防和治療 | |
| EP4003283C0 (en) | TREATMENT OF INFLAMMATORY SKIN CONDITIONS | |
| GB201706662D0 (en) | Treatment of neurological diseases | |
| GB201604253D0 (en) | Treatment of genetic diseases | |
| GB201517565D0 (en) | Treatment of genetic diseases | |
| ZA201700571B (en) | Therapeutically active compounds and their methods of use | |
| GB201514909D0 (en) | Treatment of autoimmune diseases | |
| SG10201913141UA (en) | Treatment of alphavirus-induced inflammation |